BEC BIOENERGETICS COMMUNICATIONS
Bioenerg Commun 2022.15
https://doi.org/10.26124/bec:2022-0015.r1
Open peer review
Open Access

Open peer review and authors' responses

Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets

Authors: Dambrova M, Cecatto C, Vilskersts R, Liepinsh E

Bioenerg Commun 2022.14. https://doi.org/10.26124/bec:2022-0015

Reviewer 1: Liana Silva

iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa

Manuscript reviewed 2022-07-19: *Only major points included.*

Reviewer 1

The manuscript by Dambrova et al provides a short but critical overview on acylcarnitines as potential targets for therapy. Overall, the manuscript is well written, and it covers the most fundamental aspects in the field. There is only a minor issue in table 2 that could be improved. The title of the table could be more descriptive, and the table would read better if an extra column was added to indicate separately the clinical/pre-clinical status of each drug.

Authors

A new column (Effect on plasma acylcarnitines, sample origin) is now added to the Table 2 to provide information about pre-/clinical status of drugs and effect on acylcarnitine levels. We hope that this makes the Table more informative. The table presents examples of information about some drug-induced effects on acylcarnitine concentrations. More comprehensive analysis of drug effects on acylcarnitine levels will be possible in some year time when ongoing metabolomic studies will be finalized and results published.